Melbourne, Victoria, Australia
Trajan Scientific and Medical (Trajan) has been featured by @AuManufacturing, highlighting Trajan's ongoing investment into the development of hemaPEN®, and other technologies to address emerging trends in healthcare.
The article outlines Trajan's collaborative approach to R&D, and success in identifying and manufacturing niche technologies for global markets.
Read the full article at @AUManufacturing - Pens and prospering as a manufacturer.
The hemaPEN® is a device supplied for research purposes only. This device is not for therapeutic or diagnostic use.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.